Inicio › Cáncer del colon y del recto › Massachusetts
Ensayos clínicos de Cáncer del colon y del recto en Massachusetts
63 estudios sobre Cáncer del colon y del recto buscan participantes en Massachusetts.
Ciudades en Massachusetts
Texto oficial del estudio (inglés)
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06324357The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06565052A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07578571A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Boston
- Research Site, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT05877599A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- Dana-Farber Cancer Institute /ID# 270624, Boston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06820463Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
- Dana-Farber Brigham Cancer Center - Foxborough, Foxborough
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07222800Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06218914Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06047379Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06128551Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06445062A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07213791A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07114601A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Massachusetts General Hospital - Main Campus, Boston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07349537Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT05786924The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT04585750A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Massachusetts General Hospital, Boston
- Oncura Health, Boston
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT07284849Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
- Dana Farber Cancer Institute, Boston
Reclutando
Edades de 18 a 50 · Todos los sexos · Actualizado el 11 sept 2026 · NCT06202183Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT04899908Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT06625775Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
- Boston Medical Center, Boston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT05673148A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06760819A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital (MG), Boston
ReclutandoFase 1
Edades de 18 a 99 · Todos los sexos · Actualizado el 1 sept 2026 · NCT06983743A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 ago 2026 · NCT07544589A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- Mass General Cancer Center, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 ago 2026 · NCT07227168Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1/2
12 Months – 30 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT04851119MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 ago 2026 · NCT06586515Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT05410977FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05919264A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 ago 2026 · NCT05592626Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #7, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT05176483AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 jul 2026 · NCT07094113A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital - Dana Farber, Boston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 jul 2026 · NCT03526835Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Massachusetts General Hospital, Boston
ReclutandoFase 1
Edades de 18 a 100 · Todos los sexos · Actualizado el 29 jul 2026 · NCT06562192A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jul 2026 · NCT06179160A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jul 2026 · NCT06131840A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
- Massachusetts General Hospital /ID# 273608, Boston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jul 2026 · NCT07023289A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
- Dana-Farber/Massachusetts General Hospital, Inc, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 jul 2026 · NCT07300150A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 jun 2026 · NCT07458347A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
- Massachusetts General Hospital Cancer Center, Boston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 jun 2026 · NCT06412198De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.